

Jonathan G Howlett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2651178/publications.pdf>

Version: 2024-02-01

153
papers

16,529
citations

31902

53
h-index

15683

125
g-index

159
all docs

159
docs citations

159
times ranked

14729
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	13.9	4,108
2	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	13.9	1,133
3	Effects of Exercise Training on Health Status in Patients With Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1451.	3.8	631
4	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	0.8	503
5	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018, 34, 506-525.	0.8	474
6	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 549-568.	0.8	431
7	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016, 32, 569-588.	0.8	400
8	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
9	Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. <i>Canadian Journal of Cardiology</i> , 2006, 22, 23-45.	0.8	378
10	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	3.8	340
11	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020, 36, 596-624.	0.8	324
12	N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure. <i>Circulation</i> , 2007, 115, 3103-3110.	1.6	299
13	HFSA 2006 Comprehensive Heart Failure Practice Guideline: Introduction and Table of Contents. <i>Journal of Cardiac Failure</i> , 2006, 12, e1-e2.	0.7	288
14	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations. <i>Heart Rhythm</i> , 2008, 5, 907-925.	0.3	279
15	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017, 33, 557-576.	0.8	269
16	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	2.9	264
17	Effects of Exercise Training on Depressive Symptoms in Patients With Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 465-74.	3.8	239
18	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 485-501.	0.8	221

#	ARTICLE	IF	CITATIONS
19	ESC/AHA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations: Developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Fail. <i>Europace</i> , 2008, 10, 707-725.	0.7	215
20	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. <i>Canadian Journal of Cardiology</i> , 2010, 26, 249-258.	0.8	191
21	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 168-181.	0.8	176
22	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. <i>Canadian Journal of Cardiology</i> , 2012, 28, 270-287.	0.8	173
23	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	0.8	170
24	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2013, 29, 528-542.	0.8	163
25	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	1.0	151
26	The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 726-733.	1.2	149
27	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. <i>Canadian Journal of Cardiology</i> , 2011, 27, 319-338.	0.8	139
28	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. <i>Canadian Journal of Cardiology</i> , 2007, 23, 21-45.	0.8	131
29	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
30	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. <i>Canadian Journal of Cardiology</i> , 2010, 26, 185-202.	0.8	125
31	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
32	Relation of Depression to Severity of Illness in Heart Failure (from Heart Failure And a Controlled) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 103, 1285-1289.	0.7	113
33	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. <i>Canadian Journal of Cardiology</i> , 2009, 25, 287-298.	0.8	111
34	The Relationship of Quality of Life, Depression, and Caregiver Burden in Outpatients With Congestive Heart Failure. <i>Congestive Heart Failure</i> , 2005, 11, 303-310.	2.0	107
35	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. <i>Canadian Journal of Cardiology</i> , 2015, 31, 3-16.	0.8	96
36	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. <i>Canadian Journal of Cardiology</i> , 2008, 24, 21-40.	0.8	93

#	ARTICLE	IF	CITATIONS
37	Extent of Coronary and Myocardial Disease and Benefit From Surgical Revascularization in LV Dysfunction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 553-561.	1.2	92
38	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	1.0	90
39	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	0.8	89
40	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016, 32, 296-310.	0.8	86
41	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	2.9	86
42	Treating the right patient at the right time: Access to heart failure care. <i>Canadian Journal of Cardiology</i> , 2006, 22, 749-754.	0.8	82
43	Prospective Evaluation of Nocturnal Oximetry for Detection of Sleep-Related Breathing Disturbances in Patients With Chronic Heart Failure. <i>Chest</i> , 2005, 127, 1507-1514.	0.4	81
44	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. <i>Canadian Journal of Cardiology</i> , 2009, 25, 85-105.	0.8	79
45	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy". <i>Canadian Journal of Cardiology</i> , 2008, 24, 465-475.	0.8	78
46	The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. <i>CMAJ Open</i> , 2016, 4, E365-E370.	1.1	73
47	Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. <i>Hypertension</i> , 2008, 51, 48-54.	1.3	69
48	Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 322-334.	0.8	68
49	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. <i>Lancet</i> , 2022, 399, 1391-1400.	6.3	67
50	Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β -blocker therapy: data from the HF-ACTION trial. <i>European Heart Journal</i> , 2013, 34, 2271-2280.	1.0	63
51	Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. <i>European Heart Journal</i> , 2019, 40, 2110-2117.	1.0	63
52	A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: The impact of beta-blockade. <i>Canadian Journal of Cardiology</i> , 2006, 22, 769-772.	0.8	60
53	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	3.0	59
54	Quality-of-Life Outcomes With Coronary Artery Bypass Graft Surgery in Ischemic Left Ventricular Dysfunction. <i>Annals of Internal Medicine</i> , 2014, 161, 392.	2.0	58

#	ARTICLE	IF	CITATIONS
55	Prognostic Value of Right Ventricular Strain Using Speckle-Tracking Echocardiography in Pulmonary Hypertension: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1069-1078.	0.8	54
56	Exercise Capacity and Cardiovascular Adaptations to Aerobic Training Early After Stroke. <i>Topics in Stroke Rehabilitation</i> , 2005, 12, 31-44.	1.0	52
57	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
58	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
59	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. <i>Canadian Journal of Cardiology</i> , 2014, 30, 249-263.	0.8	44
60	Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2019, 25, 147-153.	0.7	44
61	External Validation of the H ₂ F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2019, 139, 2377-2379.	1.6	44
62	Palliative care in heart failure: addressing the largest care gap. <i>Current Opinion in Cardiology</i> , 2011, 26, 144-148.	0.8	40
63	Determinants of Early Readmission After Hospitalization for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 612-618.	0.8	40
64	Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 932-942.	2.9	40
65	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2019, 7, 878-887.	1.9	37
66	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	1.2	36
67	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.	2.9	36
68	Conversion From Cyclosporine Microemulsion to Tacrolimus-Based Immunosuppression Improves Cholesterol Profile in Heart Transplant Recipients With Treated but Persistent Dyslipidemia: The Canadian Multicentre Randomized Trial of Tacrolimus vs Cyclosporine Microemulsion. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 798-809.	0.3	35
69	Heart failure clinics are associated with clinical benefit in both tertiary and community care settings: Data from the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) registry. <i>Canadian Journal of Cardiology</i> , 2009, 25, S306-S311.	0.8	35
70	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35
71	Current state of cardiac amyloidosis. <i>Current Opinion in Cardiology</i> , 2013, 28, 242-248.	0.8	34
72	End-of-life planning in heart failure: It should be the end of the beginning. <i>Canadian Journal of Cardiology</i> , 2010, 26, 135-141.	0.8	33

#	ARTICLE	IF	CITATIONS
73	Outcomes in patients undergoing cardiac retransplantation: A propensity matched cohort analysis of the UNOS Registry. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1067-1074.	0.3	33
74	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	2.9	33
75	A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 632-643.	0.8	31
76	Implantable Cardioverter-Defibrillator Implantation as a Bridge to Cardiac Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1336-1339.	0.3	30
77	Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study. <i>Transplant International</i> , 2010, 23, 31-37.	0.8	30
78	The Canadian Heart Health Strategy and Action Plan: Cardiac rehabilitation as an exemplar of chronic disease management. <i>Canadian Journal of Cardiology</i> , 2010, 26, 37-41.	0.8	30
79	Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. <i>ESC Heart Failure</i> , 2017, 4, 301-311.	1.4	28
80	The Effect of Comorbidity on the Competing Risk of Sudden and Nonsudden Death in an Ambulatory Heart Failure Population. <i>Canadian Journal of Cardiology</i> , 2011, 27, 254-261.	0.8	27
81	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 91.	0.7	27
82	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	26
83	Cyclosporine Reduction in the Presence of Everolimus: 3-Month Data From a Canadian Pilot Study of Maintenance Cardiac Allograft Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 197-202.	0.3	25
84	Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 534-542.	0.9	25
85	Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2015, 31, 792-799.	0.8	25
86	The Need for Heart Failure Advocacy in Canada. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1450-1454.	0.8	25
87	Posterior annular plication: tricuspid valve repair in Ebstein's anomaly. <i>Annals of Thoracic Surgery</i> , 2004, 77, 2167-2171.	0.7	24
88	Nebivolol: Vasodilator Properties and Evidence for Relevance in Treatment of Cardiovascular Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, S29-S37.	0.8	24
89	Ivabradine in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	23
90	Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e017278.	1.6	23

#	ARTICLE	IF	CITATIONS
91	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	1.9	22
92	Randomized, Placebo-Controlled Trial of the Angiotensin Receptor Antagonist Losartan for Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2021, 90, 473-481.	0.7	21
93	Should We Perform a Heart Failure Risk Score?. <i>Circulation: Heart Failure</i> , 2013, 6, 4-5.	1.6	20
94	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020, 43, 2878-2881.	4.3	20
95	The Effect of Spironolactone Use on Heart Failure Mortality: A Population-Based Study. <i>Journal of Cardiac Failure</i> , 2007, 13, 165-169.	0.7	17
96	Benefit of Neoral C2 Monitoring in De Novo Cardiac Transplant Recipients Receiving Basiliximab Induction. <i>Transplantation</i> , 2008, 85, 992-999.	0.5	17
97	Initiation of ivabradine in cardiogenic shock. <i>ESC Heart Failure</i> , 2019, 6, 1088-1091.	1.4	16
98	A qualitative study of the current state of heart failure community care in Canada: what can we learn for the future?. <i>BMC Health Services Research</i> , 2015, 15, 290.	0.9	15
99	Identifying opportunities to address the congestive heart failure burden: the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. <i>Canadian Journal of Cardiology</i> , 2003, 19, 439-44.	0.8	15
100	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016.	1.0	15
101	Factors Associated With 7-Day Rehospitalization After Heart Failure Admission. <i>Journal of Cardiovascular Nursing</i> , 2017, 32, 339-347.	0.6	14
102	Evidence of increasing public participation in advance care planning: a comparison of polls in Alberta between 2007 and 2013. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, 189-196.	0.8	13
103	Cardiovascular Fitness and Adaptations to Aerobic Training after Stroke. <i>Physiotherapy Canada</i> <i>Physiotherapie Canada</i> , 2006, 58, 103-113.	0.3	12
104	Specialist Heart Failure Clinics Must Evolve to Stay Relevant. <i>Canadian Journal of Cardiology</i> , 2014, 30, 276-280.	0.8	12
105	Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. <i>ESC Heart Failure</i> , 2018, 5, 172-183.	1.4	12
106	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	3.0	12
107	Cardiac remodelling predicts outcome in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2021, 8, 5352-5362.	1.4	12
108	Canadian Consensus on cardiac transplantation in pediatric and adult congenital heart disease patients 2004: executive summary. <i>Canadian Journal of Cardiology</i> , 2005, 21, 1145-7.	0.8	12

#	ARTICLE	IF	CITATIONS
109	Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction. <i>CJC Open</i> , 2020, 2, 447-453.	0.7	11
110	Acute Heart Failure: Lessons Learned So Far. <i>Canadian Journal of Cardiology</i> , 2011, 27, 284-295.	0.8	10
111	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1282-1292.	0.8	10
112	Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2015, 30, 168-172.	0.8	10
113	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. <i>ESC Heart Failure</i> , 2018, 5, 19-26.	1.4	10
114	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020, 2, 151-160.	0.7	10
115	Determinants and Prognostic Significance of Serial Right Heart Function Changes in Patients With Cardiac Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 432-440.	0.8	10
116	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 52-64.	1.9	10
117	Metabolic Syndrome and Its Components in Individuals Undergoing Rehabilitation After Stroke. <i>Journal of Neurologic Physical Therapy</i> , 2009, 33, 189-194.	0.7	8
118	Relationships among achieved heart rate, β -blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation. <i>Open Heart</i> , 2016, 3, e000520.	0.9	7
119	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2725-2733.	1.4	7
120	Physician specialty and quality of care for CHF: different patients or different patterns of practice?. <i>Canadian Journal of Cardiology</i> , 2003, 19, 371-7.	0.8	7
121	Canadian Cardiovascular Society Consensus Conference 2002: Management of heart disease in the elderly patient. <i>Canadian Journal of Cardiology</i> , 2004, 20 Suppl A, 7A-16A.	0.8	5
122	Surgical Treatment of Ischemic Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2011, 17, 971-972.	0.7	4
123	Retrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarction. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 46.	0.7	4
124	Does heart rate really matter to patients with heart failure?. <i>Current Opinion in Cardiology</i> , 2017, 32, 209-216.	0.8	4
125	Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population. <i>Circulation: Heart Failure</i> , 2020, 13, e006952.	1.6	4
126	The International Endomyocardial Biopsy Position Paper: A Basis for Integration Into Modern Clinical Practice. <i>Journal of Cardiac Failure</i> , 2022, 28, e5-e7.	0.7	4

#	ARTICLE	IF	CITATIONS
127	Thrombus formation on an atrial septal defect closure device. Canadian Journal of Cardiology, 2005, 21, 68-70.	0.8	4
128	Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction. Expert Review of Cardiovascular Therapy, 2008, 6, 199-208.	0.6	3
129	A Case of Palpitations Due to T-Wave Oversensing Caused by Sacubitril/Valsartan. Canadian Journal of Cardiology, 2018, 34, 1089.e1-1089.e3.	0.8	3
130	Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811880483.	0.6	3
131	Computerized Electronic Order Set: Use and Outcomes for Heart Failure Following Hospitalization. CJC Open, 2020, 2, 497-505.	0.7	3
132	The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1483-1485.	2.9	3
133	Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk. ESC Heart Failure, 2022, 9, 1564-1573.	1.4	3
134	Response to Letter Regarding Article, "N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study". Circulation, 2008, 117, .	1.6	2
135	Dancing Cats, Heart Failure, and Circulating Troponin. Journal of Cardiac Failure, 2019, 25, 238-239.	0.7	2
136	Cautious optimism for machine learning techniques for prediction of heart failure outcomes. European Journal of Heart Failure, 2021, 23, 1000-1001.	2.9	2
137	Caregiver burden and depression in heart failure and its relationship with patient depression and quality of life. Journal of Cardiac Failure, 2003, 9, S106.	0.7	1
138	AB15-1. Heart Rhythm, 2006, 3, S30.	0.3	1
139	I have heart failure " what happens now, Doc?. Canadian Journal of Cardiology, 2009, 25, 695-696.	0.8	1
140	Integration of monitoring technology for heart failure. Current Opinion in Cardiology, 2012, 27, 130-136.	0.8	1
141	Does Slow and Steady Win the Race?. Journal of the American College of Cardiology, 2012, 59, 1796-1798.	1.2	1
142	Amyloidosis Tissue Confirmation for Tafamidis Eligibility—Using Transverse Carpal Ligament and Tenosynovium Biopsy. Canadian Journal of Cardiology, 2022, 38, 1643-1646.	0.8	1
143	Percutaneous ASD closure in the setting of left ventricular failure without test balloon occlusion: mid term results. Journal of Cardiac Failure, 2003, 9, S47.	0.7	0
144	Acutely decompensated congestive heart failure: new therapies for an old problem. Expert Review of Cardiovascular Therapy, 2005, 3, 925-936.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Pancytopenia With Hypercellular Bone Marrow Secondary to Cytomegalovirus After Cardiac Transplant. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 749-750.	0.3	0
146	Cardiovascular Comorbidities in Patients at the Time of Their Network Entry Visit to Specialized Heart Failure Outpatient Clinics in the Canadian Heart Failure Network (CHFNet) 1999 to 2007. <i>Journal of Cardiac Failure</i> , 2009, 15, S108.	0.7	0
147	Traitement du diabète chez les personnes atteintes d'insuffisance cardiaque. <i>Canadian Journal of Diabetes</i> , 2013, 37, S501-S503.	0.4	0
148	Predictors for Performance of Left Ventricular Ejection Fraction Following Diagnosis of Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, S31-S32.	0.7	0
149	Heart failure guidelines fail. <i>Cmaj</i> , 2015, 187, 912.2-912.	0.9	0
150	The promise of patient-reported outcomes: one step closer to routine care. <i>European Journal of Heart Failure</i> , 2018, 20, 697-699.	2.9	0
151	Positive Recommendation for Angiotensin Receptor–Neprilysin Inhibitor: First Medication Approval for Heart Failure Without Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 528-530.	0.8	0
152	Untying the Gordian knot of sex and heart failure therapy. <i>European Journal of Heart Failure</i> , 2021, 23, 1485-1487.	2.9	0
153	Should we inhibit angiotensin-converting enzymes in acute heart failure?. <i>Heart Failure Monitor</i> , 2007, 5, 70-6.	0.7	0